Shawn Aaron profile picture

Contact Information

Shawn Aaron, MD, FRCPC
613-737-8899 ext. 74729
saaron@ohri.ca

Dr. Shawn Aaron
Division Director- Respirology
Professor, University of Ottawa
501 Smyth Road
Ottawa, ON
K1H 8L6
Canada

Phone: 613-739-6636
Fax: 613-739-6807

Funding

* = Principal Investigator (I am the principal investigator on all grants listed, unless otherwise noted)
# = Co-Investigator

2014-2019 $934,000# CIHR (PI: Dr. K. Lavoie)
Optimizing physician training in motivational communication (MC) skills for health behavior change

2014-2017 $1,048,564* Ontario Ministry of Health (Co-PI with: Dr. A. Gershon)
The Ontario COPD Population Health Network.

2013-2018 $7,553,000* CIHR Emerging Network Grant (PI)
The Canadian Respiratory Research Network.

2014-2015 $100,000# CIHR (PI: Dr. K. Lavoie)
Optimizing physician training in motivational interviewing to improve compentency, patient health behaviors, and morbidity among patients with cardiovascular and chronic lung disease

2013-14 $100,000# CIHR (PI: Dr. B. Hutton)
Adding clarity to uncertainty in the field of drug safety.

2013 $30,000* CIHR
The Canadian Respiratory Research Network: Exploring the Origin and Progression of Airway Disease.

2013-14 $51,000* PSI (Co-PI with: Dr. N. Srour)
lmpact of infection with transmissible strains of Pseudomonas aeruginosa in CF lung transplant recipients.

2013-2014 $100,000 # CIHR (PI: Dr. V. Pepin)
Optimization of pulmonary rehabilitation programmes: the OPTION study.

2012-2013 $70,350* Canadian CF Foundation
Acute effects of viral respiratory infection on chronic endobronchial P. aeruginosa infection in patients with CF.

2011-2015 $1,954,258* CIHR
Simvastatin therapy for moderate and severe COPD (STATCOPE).

2011-2016 $935,738* CIHR
Strategies to improve diagnosis and treatment of asthma in Canadians

2011-2012 $100,000* CIHR
STATCOPE Trial Bridge Funding

2011-2014 $1,051,344 # CIHR (PI: Dr. J. Bourbeau)
Canadian Cohort Obstructive Lung Disease (CANCOLD)

2011-2015 $852,287 # CIHR (PI: Dr. I. Stiell)
RAD Study Phase 2: Validation of the Canadian Heart Failure and COPD risk scores

2010-2011 $15,000 # CIHR (PI: Dr. G. Alvarez)
Smoking, tuberculosis and obstructive lung disease in Nunavut, Evaluating a Lung Health Program.

2010-2012 $171,938* CIHR
Dissemination and implementation of a lung transplant decision aid

2010-2011 $100,000* CIHR
Simvastatin for treatment of moderate and severe COPD.

2009-2014 $1,761,560# CIHR (PI: Dr. Y. Lacasse)
Multicenter randomized placebo controlled trial of nocturnal oxygen treatment in COPD -The CANOX trial.

2009-2011 $427,933# CIHR (PI: Dr. J. Bourbeau)
Canadian Cohort Obstructive Lung Disease (CANCOLD).

2009-2013 $479,053# CIHR (PI: Dr. S. Khan)
Prospective Evaluation of Long-Term Outcomes after Pulmonary Embolism (ELOPE)

2008-2011 $370,675* CIHR
TNF-alpha antagonists for acute exacerbations of COPD.

2008-2009 $50,000* Ontario Thoracic Society Grant In Aid
TNF-alpha antagonists for acute exacerbations of COPD. (grant refused- overlap with CIHR grant).

2008-2009 $19,000# Ontario Regional Cancer Foundation (PI: Dr. K. Amjadi)
Outpatient pleurodesis using sclerosants (OPUS) trial.

2008-2009 $13,680# Ontario Thoracic Society Block Term (PI: Dr. Amjadi)
Outpatient pleurodesis using sclerosants (OPUS) trial.

2008 $7500* Ontario Thoracic Society Block Term Grant
MLST to characterize two strains of P. aeruginosa infecting Canadian CF patients.

2007-2010 $220,800* Canadian Cystic Fibrosis Foundation
Treatment of aspergillus fumigatus in patients with cystic fibrosis.

2007-2009 $122,000* Physician’s Services Foundation
Treatment of aspergillus fumigatus in patients with cystic fibrosis.

2007-2010 $350,853# CIHR (Principal Investigator- Dr. Ian Stiell)
A study to develop clinical decision rules for the hospital admission of patients with acute dyspnea.

2006-2007 $59,511* (Aus) Australian CF Research Trust
Development of a decision aid for adult cystic fibrosis patients considering bilateral lung transplantation.

2005-2009 $270,000* CIHR
Detection of an epidemic strain of P aeruginosa in adult Canadian CF clinics- epidemiology and clinical implications.

2005-2007 $446,000 CIHR
Asthma in Obese Subjects- diagnostic and therapeutic strategies.

2005-2007 US$197,670 Roche Pharma Inc.
Multi analyte profiling in the characterization of the inflammatory profile in blood and induced sputum in patients with exacerbations of COPD.

2005-2007 US$208,000 Roche Pharma Inc.
Pilot study to investigate the utility of multi analyte profiling in the characterization of the inflammatory profile in blood and induced sputum in patients with stable COPD.

2005-2006 $50,000* Ontario Thoracic Society
Optimal therapy of COPD to prevent exacerbations and improve quality of life.

2005-2006 $75,000# CIHR New Frontiers Development Fund (Principal Investigator- Dr. Mark Fitzgerald).
Development of a Canadian Respiratory Clinical Trials Network.

2005-2007 $150,562# PSI (Principal Investigator- Dr. William Hodge)
Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: A double-blinded, randomized clinical trial.

2005-2007 $92,000* PSI
Development of a decision aid for adult cystic fibrosis patients considering bilateral lung transplantation.

2005-2008 $284,733* Canadian Cystic Fibrosis Foundation
Detection of an epidemic strain of P aeruginosa in adult Canadian CF clinics- epidemiology and clinical implications.

2005-2006 $8,300* Ontario Thoracic Society
Decision Aid for CF patients considering bilateral lung transplant.

2005-2006 $192,861# CIHR (Principal Investigator – Dr. Brian Rowe)
Multicenter study of anti-inflamatory treatment in asthma relapse: The AIR asthma study.

2004 $150,000* Premier’s Research Excellence Awards
Optimizing care for patients with COPD and Cystic Fibrosis.

2004 $15,000* Ontario Thoracic Society
Burkholderia cepacia complex recovered from CF patients during pulmonary exacerbations.

2003-2004 $37,500* CIHR Rx&D- Health Research Foundation
Special Research Allowance for CIHR New Investigators.

2003-2008 $250,000* CIHR New Investigator Award

2003-2006 $ 1,464,139* CIHR
Optimal therapy of COPD to prevent exacerbations and improve quality of
life. A randomized, double-blind, placebo-controlled trial.

2003-2005 $608,651# CIHR (Principal Investigator – Dr. Brian Rowe)
Controlled Trial of Antibiotic Options in Outpatients with Acute COPD exacerbation
Who Present to the Emergency Department.

2002-2003 $287,850#^ Glaxo-Smith Kline (Principal Investigator- Dr. Robert Dales)
Using spirometry to screen for airflow obstruction in primary care practice: does it improve the accuracy of diagnosis and influence clinical management?

2002 $31,000* Physician Services Inc.
Comparison of sputum vs. Protected brush cultures of P. aeruginosa in adults with CF.


2001 $11,217* Ontario Thoracic Society- Block Term
Pathophysiology of acute exacerbations of COPD.

2001 $16,200* Ontario Thoracic Society- Block Term
Comparison of sputum vs. Protected brush cultures of P. aeruginosa in adults with CF.

2001-2004 $98,526* Canadian Cystic Fibrosis Foundation
Multiple Combination Bactericidal Antibiotic Testing for multi- resistant B. cepacia and P. aeruginosa.

2001-2004 $319,225* CIHR
Multiple Combination Bactericidal AntibioticTesting for multi-resistant B. cepacia and P. aeruginosa.

2001 $12,007* Asthma Society of Canada
The Effects of Weight Reduction on Airway Reactivity in Female Subjects: A Prospective Cohort Pilot Study.

2000 $10,000* OTS- Block Term
Tetracaine Gel Prior to Arterial Puncture for Arterial Blood Gas.

2000 $10,000* OTS- Block Term
The Effects of Weight Reduction on Airway Reactivity in Female Subjects: A Prospective Cohort Pilot Study.

2000-2002 $350,272* CIHR
Controlled Trial of Steroids For Acute COPD exacerbation.